OverviewSuggest Edit

Tenaya Therapeutics is a biotechnology company that discovers, designs, develops, and delivers curative therapies that address heart diseases. It offers the Cellular Regeneration platform, the Gene Therapy platform, and the Precision Medicine platform dedicated to regenerate heart cells, restore cell function, reduce the scar area, and analyze human genetics.

TypePublic
Founded2016
HQSouth San Francisco, CA, US
Websitetenayatherapeutics.com

Latest Updates

Employees (est.) (Jun 2021)85
Share Price (Sept 2021)$20
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Tenaya Therapeutics

Faraz Ali

Faraz Ali

Chief Executive Officer, Director
Leone Patterson

Leone Patterson

Chief Financial and Business Officer
Kee-Hong Kim

Kee-Hong Kim

Senior Vice President, Manufacturing
Jay Vora

Jay Vora

Senior Vice President, Portfolio and Program Management
Matthew Pollman

Matthew Pollman

Senior Vice President, Clinical Development
Show more

Tenaya Therapeutics Office Locations

Tenaya Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
171 Oyster Point Blvd., Suite 500
Show all (1)

Tenaya Therapeutics Financials and Metrics

Tenaya Therapeutics Revenue

Market capitalization (29-Sept-2021)

826.8m

Closing stock price (29-Sept-2021)

20.0
Tenaya Therapeutics's current market capitalization is $826.8 m.
Show all financial metrics

Tenaya Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Tenaya Therapeutics Online and Social Media Presence

Embed Graph

Tenaya Therapeutics Blogs

Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021

Highly specific HDAC6 inhibitors (HDAC6i) demonstrated improved cardiac function in mouse models of heart failure with preserved ejection in fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM) Potential utility of HDAC6 as a target in heart disease was validated using Tenaya’s Precision Me…

Tenaya Therapeutics Announces New Appointments to Leadership Team

Gene therapy industry veteran Leone Patterson joins Tenaya as Chief Financial and Business Officer Cardiologist Matthew Pollman appointed as Senior Vice President, Clinical Development SOUTH SAN FRANCISCO,

Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy

TN-201 is a potentially curative gene therapy intended to address genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the Myosin Binding Protein C3 (MYBPC3) gene,

Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease

Series C round led by RTW Investments, LP; RA Capital Management; Fidelity Management & Research Company; and funds and accounts advised by T. Rowe Price Associates, Inc.; and joined by existing investors including The Column Group,

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

Our CEO, Faraz Ali, authored an article for Cell & Gene Therapy Insights discussing the opportunities and challenges of developing cell and gene therapies for cardiovascular disease. Cardiovascular diseases, especially orphan indications,

Tenaya Therapeutics Frequently Asked Questions

  • When was Tenaya Therapeutics founded?

    Tenaya Therapeutics was founded in 2016.

  • Who are Tenaya Therapeutics key executives?

    Tenaya Therapeutics's key executives are Faraz Ali, Leone Patterson and Kee-Hong Kim.

  • How many employees does Tenaya Therapeutics have?

    Tenaya Therapeutics has 85 employees.

  • Who are Tenaya Therapeutics competitors?

    Competitors of Tenaya Therapeutics include ZielBio, Synbal and Epigene Labs.

  • Where is Tenaya Therapeutics headquarters?

    Tenaya Therapeutics headquarters is located at 171 Oyster Point Blvd., Suite 500, South San Francisco.

  • Where are Tenaya Therapeutics offices?

    Tenaya Therapeutics has an office in South San Francisco.

  • How many offices does Tenaya Therapeutics have?

    Tenaya Therapeutics has 1 office.